Unlocking Opportunities: Arlington Capital Partners and Everest Clinical Research Join Forces in European Acquisition

Arlington Capital Partners and Everest Clinical Research have made a strategic move in the pharmaceutical and biotechnology industry with their acquisition of European contract research organization (CRO), August Research. This acquisition will not only provide Everest with a European base to expand its Clinical Trial Services (CTS), but it will also enhance its operational capabilities across 14 countries in Western and Eastern Europe.

The collaboration between Arlington Capital Partners, Everest Clinical Research, and DLA Piper has brought together their industry knowledge and global capabilities to facilitate this significant acquisition. Leading the deal team, Jeffrey Houle, co-chair of DLA Piper’s Aerospace, Defense and Government Services Transactional Practice, expressed his pleasure in assisting with this strategic acquisition.

DLA Piper played a pivotal role in advising Arlington Capital Partners and Everest by providing their expertise across various locations. The team consisted of partners from multiple offices, including Tom Pilkerton (Baltimore), Ute Krudewagen (Palo Alto), Russell Drew (Toronto), Peter Somekh (Dubai), Marco De Morpurgo (Rome), and Oana Dutu-Buzura (Bucharest). Additionally, senior attorney Cara Hupprich (Northern Virginia), legal director Luis Borrero Zorita (Madrid), and associates Blanka Borzonsyi (Budapest), Jakub Niemiec (Warsaw), and Sophie Mills (Leeds) also contributed their skills to the acquisition.

DLA Piper, a global law firm, is well-equipped to handle complex transactions with its extensive team of corporate lawyers located across the globe. With over 1,000 corporate lawyers, DLA Piper has consistently been rated number one in global M&A volume for 12 consecutive years, according to Mergermarket.

About Everest Clinical Research Corporation:

Everest Clinical Research Corporation is a full-service contract research organization (CRO) that specializes in providing clinical research services to the pharmaceutical, biotechnology, and medical device industries. Operating primarily in North America, Everest has established itself as a statistical and data management center of excellence since its founding in 2004. With its headquarters in Toronto, Canada, and additional offices in the United States, China, and Taiwan, Everest is known for its high-quality deliverables, superior customer service, and flexibility in meeting clients' needs.

About Arlington Capital Partners:

Arlington Capital Partners is a private equity firm based in Washington, DC, managing approximately $7 billion in capital commitments. The firm focuses on middle-market investment opportunities in growth industries such as healthcare, government services and technology, aerospace & defense, and business services and software. With a unique combination of operating and private equity experience, Arlington works in partnership with motivated management teams to establish and advance their companies' positions as leading competitors in their field.

About DLA Piper:

DLA Piper is a global law firm with a strong presence in over 40 countries, covering the Americas, Europe, the Middle East, Africa, and Asia Pacific. With their extensive network, DLA Piper is well-positioned to support clients with their legal needs worldwide. It is important to note that in certain jurisdictions, this information may be considered attorney advertising.

In conclusion, the joint acquisition by Arlington Capital Partners and Everest Clinical Research marks a significant move in the biotechnology and pharmaceutical industry. With DLA Piper providing expert legal counsel, this strategic acquisition will strengthen Everest's global service offerings and solidify its position in one of the largest clinical trial markets in the world. The collaboration between these industry leaders sets the stage for future growth opportunities and advancements in research and development within the pharmaceutical sector.